Anti-Mouse CD183 (Clone CXCR3-173) – Purified in vivo GOLD™ Functional Grade

Mouse N-terminus of CXCR3

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -70°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

CXCR3-173 activity is directed against murine CD183 (CXCR3).

CXCL3 is expressed on primary memory phenotype CD4⁺ and CD8⁺ T cells, naturally occurring CD4⁺CD25⁺ Foxp3⁺ regulatory T cells, natural killer (NK) T cells, and approximately 25% of NK cells. CXCR3-173 recognizes an epitope of CXCR3 expressed on the surface of activated mouse splenocytes.

CXCR3 (CD183) is a chemokine receptor that binds to three ligands, CXCL9 (MIG), CXCL10 (IP-10), and CXCL11 (ITAC), that are induced by IFNγ, -α/β, or other proinflammatory cytokines¹. CXCR3 is important for natural killer (NK) cell-dependent priming of CD4⁺ T cells in lymph nodes², host responses to infection³, and CD4⁺ T cell responses to allografts^4,5.

CXCR3-173 was generated by immunizing Armenian hamsters with a peptide sequence unique to mouse CXCR3 which encompasses amino acids 1-37^6,7. Hamsters were tested by ELISA for seropositivity against CXCR3 peptide and hybridomas were generated, screened by FACS, purified, and tested for: staining, CXCR3 blockade in vitro, and endotoxin levels⁶. CXCR3-173 detects the native form of CXCR3, and therefore does not work in Western blotting.

CXCR3-173 has potential use in immunotherapeutic approaches to inhibit transplant rejection and immune related diseases⁶. In vitro, CXCR3-173 blocks chemotaxis in response to CXCL10 or CXCL11 but not CXCL9. In vivo, CXCR3-173 prolongs both cardiac and islet allograft survival in a manner further enhanced by rapamycin.

1. Tokunaga R, Zhang W, Naseem M, et al. Cancer Treat Rev. 63:40-47. 2018.
2. Martin-Fontecha A, Thomsen LL, Brett S, et al. Nat Immunol. 5: 1260-1265. 2004.
3. Khan IA, MacLean JA, Lee FS, et al. Immunity. 12: 483-494. 2000.
4. Hancock WW, Lu B, Gao W, et al. J Exp Med. 192: 1515-1520. 2000.
5. Hancock WW, Gao W, Csizmadia V, et al. J Exp Med. 193: 975-980. 2001.
6. Uppaluri R, Sheehan KC, Wang L, et al. Transplantation. 86(1):137-147. 2008.
7. Krug A, Uppaluri R, Facchetti F, et al. J Immunol. 169(11):6079-6083. 2002.